The Effect of Darapladib Therapy for the Expression of Lp-PLA2 in Dyslipidemia and Type 2 Diabetes Mellitus Atherosclerosis Model

Show simple item record

dc.contributor.author Wihastuti, Titin Andri
dc.contributor.author Lestari, Rosaria Dian
dc.contributor.author Heriansyah, Teuku
dc.date.accessioned 2021-10-14T01:50:45Z
dc.date.available 2021-10-14T01:50:45Z
dc.date.issued 2018-04-29
dc.identifier.issn 2231-3354
dc.identifier.uri https://www.japsonline.com/admin/php/uploads/2601_pdf.pdf
dc.identifier.uri http://repository.unisma.ac.id/handle/123456789/2036
dc.description [ARCHIVES] Copyright Article from: Journal of Applied Pharmaceutical Science en_US
dc.description.abstract Atherosclerosis is the main cause of mortality and morbidity globally. Lipoprotein-associated phospholipase A2 (LpPLA2 ) activity is suspected to have a significant role in atherosclerosis. 50 Sprague-Dawley Rats were divided into five groups: normal, dyslipidemia, Type 2 diabetes mellitus (T2DM), dyslipidemia with darapladib administration and T2DM with darapladib administration. These groups were divided into two serial times: 8 and 16 weeks. mRNA Lp-PLA2 was measured from blood and aortic tissue extraction. Aortic tissue Lp-PLA2 was measured by immunofluorescence. Lp-PLA2 expression in aortic tissue was consistently increased in dyslipidemia and T2DM. The expression of Lp-PLA2 enzymatic was significantly suppressed (p < 0.05) with the administration of darapladib especially in 8 weeks groups in both dyslipidemia and T2DM. The administration of darapladib in dyslipidemia and T2DM didn’t significantly suppress the expression of mRNA Lp-PLA2 in blood and aortic tissue. The failure of genetic expression suppression of Lp-PLA2 was found in both 8 weeks and 16 weeks groups. The expression of Lp-PLA2 protein also showed an inclined difference between dyslipidemia and T2DM. These results showed that administration of darapladib significantly decreased Lp-PLA2 protein but prone to increase the expression of mRNA Lp-PLA2 in blood and aortic tissue in dyslipidemia and T2DM model en_US
dc.language.iso en en_US
dc.publisher Journal of Applied Pharmaceutical Science en_US
dc.relation.ispartofseries Journal of Applied Pharmaceutical Science;Vol.8, Issue 4, Page 64-70
dc.subject Darapladib en_US
dc.subject Dyslipidemia en_US
dc.subject Atherosclerosis en_US
dc.subject T2DM en_US
dc.subject Lp-PLA2 en_US
dc.title The Effect of Darapladib Therapy for the Expression of Lp-PLA2 in Dyslipidemia and Type 2 Diabetes Mellitus Atherosclerosis Model en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Kolom Pencarian


Browse

My Account